Moss, 12 March 2026
Reference is made to Gentian Diagnostics ASA's (the "Company") stock exchange announcement earlier today regarding the offer of new shares to employees in the Company and its subsidiaries under the Gentian Employee Share Purchase Program (the "Employee Share Purchase Program") and the board of directors’ resolution to increase the share capital of the Company. The application period expired on 11 March 2026 at 16:00 CET. Under the program, each participating employee could subscribe for shares for a maximum total subscription amount of NOK 100,000.
The following primary insiders of the Company have applied for, been allocated and subscribed for new shares in the Company at the offer price of NOK 32.58 per share in the Employee Share Purchase Program:
Matti Heinonen, CEO, has subscribed for NOK 100,000 in the Company, corresponding to 3,069 new shares. Following the subscription, Mr. Heinonen holds 10,569 shares and 100,000 options in the Company.
Njaal Kind, CFO, has subscribed for NOK 100,000 in the Company, corresponding to 3,069 new shares. Following the subscription, Mr. Kind holds 32,194 shares and 140,670 options in the Company.
Frank Frantzen, CTO, has subscribed for NOK 100,000 in the Company, corresponding to 3,069 new shares. Following the subscription, Mr. Frantzen holds 26,184 shares and 50,000 options in the Company.
Aleksandra Havelka, CSO, has subscribed for NOK 30,000 in the Company, corresponding to 920 new shares. Following the subscription, Ms. Havelka holds 2,920 shares and 80,000 options in the Company.
Ole Sørlie, Business Controller, has subscribed for NOK 100.000 in the Company, corresponding to 3,069 new shares. Following the subscription, Mr. Sørlie holds 8,189 shares in the Company.
Attached to this announcement is supplementary information regarding primary insiders’ share subscriptions.
For further information, please contact:
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for better treatment decisions. Gentian’s expertise and focus lie within immunoassays, specifically for infections, inflammation, kidney disease and heart failure. By converting existing and clinically relevant biomarkers to the most efficient, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.